Form 4: Quince Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Christopher J. Senner, a director of Quince Therapeutics, Inc., acquired 27,000 employee stock options on June 5, 2024.
Summary
- Christopher J. Senner, a director at Quince Therapeutics, Inc., filed a Form 4 on June 7, 2024, reporting a transaction.
- On June 5, 2024, Senner acquired 27,000 employee stock options with an exercise price of $0.82.
- These options vest 100% on the one-year anniversary of the grant date, June 5, 2025, and expire on June 5, 2034.
- Following the transaction, Senner directly owns 27,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment, as it can be interpreted as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: Christopher J. Senner acquired employee stock options. |
| 06/05/2025 | Vesting date: 100% of the shares subject to the stock option will vest. |
| 06/05/2034 | Expiration date of the stock options. |
| 06/07/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.